Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
Abstract Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease that affects over 30% of the world’s population. For decades, the heterogeneity of non-alcoholic fatty liver disease (NAFLD) has impeded our understanding of the disease mechanism...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-04-01
|
| Series: | Lipids in Health and Disease |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12944-024-02092-2 |
| _version_ | 1827291364676599808 |
|---|---|
| author | Yuxiao Jiang Lili Wu Xiaopeng Zhu Hua Bian Xin Gao Mingfeng Xia |
| author_facet | Yuxiao Jiang Lili Wu Xiaopeng Zhu Hua Bian Xin Gao Mingfeng Xia |
| author_sort | Yuxiao Jiang |
| collection | DOAJ |
| description | Abstract Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease that affects over 30% of the world’s population. For decades, the heterogeneity of non-alcoholic fatty liver disease (NAFLD) has impeded our understanding of the disease mechanism and the development of effective medications. However, a recent change in the nomenclature from NAFLD to MASLD emphasizes the critical role of systemic metabolic dysfunction in the pathophysiology of this disease and therefore promotes the progress in the pharmaceutical treatment of MASLD. In this review, we focus on the mechanism underlying the abnormality of hepatic lipid metabolism in patients with MASLD, and summarize the latest progress in the therapeutic medications of MASLD that target metabolic disorders. |
| first_indexed | 2024-04-24T12:35:46Z |
| format | Article |
| id | doaj.art-1035c0b9bc534f42bdfcf2fdf604942f |
| institution | Directory Open Access Journal |
| issn | 1476-511X |
| language | English |
| last_indexed | 2024-04-24T12:35:46Z |
| publishDate | 2024-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Lipids in Health and Disease |
| spelling | doaj.art-1035c0b9bc534f42bdfcf2fdf604942f2024-04-07T11:28:52ZengBMCLipids in Health and Disease1476-511X2024-04-0123111310.1186/s12944-024-02092-2Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeuticsYuxiao Jiang0Lili Wu1Xiaopeng Zhu2Hua Bian3Xin Gao4Mingfeng Xia5Department of Endocrinology and Metabolism, Zhongshan Hospital and Fudan Institute for Metabolic Diseases, Fudan UniversityDepartment of Endocrinology and Metabolism, Zhongshan Hospital and Fudan Institute for Metabolic Diseases, Fudan UniversityDepartment of Endocrinology and Metabolism, Zhongshan Hospital and Fudan Institute for Metabolic Diseases, Fudan UniversityDepartment of Endocrinology and Metabolism, Zhongshan Hospital and Fudan Institute for Metabolic Diseases, Fudan UniversityDepartment of Endocrinology and Metabolism, Zhongshan Hospital and Fudan Institute for Metabolic Diseases, Fudan UniversityDepartment of Endocrinology and Metabolism, Zhongshan Hospital and Fudan Institute for Metabolic Diseases, Fudan UniversityAbstract Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease that affects over 30% of the world’s population. For decades, the heterogeneity of non-alcoholic fatty liver disease (NAFLD) has impeded our understanding of the disease mechanism and the development of effective medications. However, a recent change in the nomenclature from NAFLD to MASLD emphasizes the critical role of systemic metabolic dysfunction in the pathophysiology of this disease and therefore promotes the progress in the pharmaceutical treatment of MASLD. In this review, we focus on the mechanism underlying the abnormality of hepatic lipid metabolism in patients with MASLD, and summarize the latest progress in the therapeutic medications of MASLD that target metabolic disorders.https://doi.org/10.1186/s12944-024-02092-2Metabolic dysfunction-associated fatty liver diseaseHepatic lipid metabolismMultisystem diseasePathophysiologyMedicationsClinical trials |
| spellingShingle | Yuxiao Jiang Lili Wu Xiaopeng Zhu Hua Bian Xin Gao Mingfeng Xia Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics Lipids in Health and Disease Metabolic dysfunction-associated fatty liver disease Hepatic lipid metabolism Multisystem disease Pathophysiology Medications Clinical trials |
| title | Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics |
| title_full | Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics |
| title_fullStr | Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics |
| title_full_unstemmed | Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics |
| title_short | Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics |
| title_sort | advances in management of metabolic dysfunction associated steatotic liver disease from mechanisms to therapeutics |
| topic | Metabolic dysfunction-associated fatty liver disease Hepatic lipid metabolism Multisystem disease Pathophysiology Medications Clinical trials |
| url | https://doi.org/10.1186/s12944-024-02092-2 |
| work_keys_str_mv | AT yuxiaojiang advancesinmanagementofmetabolicdysfunctionassociatedsteatoticliverdiseasefrommechanismstotherapeutics AT liliwu advancesinmanagementofmetabolicdysfunctionassociatedsteatoticliverdiseasefrommechanismstotherapeutics AT xiaopengzhu advancesinmanagementofmetabolicdysfunctionassociatedsteatoticliverdiseasefrommechanismstotherapeutics AT huabian advancesinmanagementofmetabolicdysfunctionassociatedsteatoticliverdiseasefrommechanismstotherapeutics AT xingao advancesinmanagementofmetabolicdysfunctionassociatedsteatoticliverdiseasefrommechanismstotherapeutics AT mingfengxia advancesinmanagementofmetabolicdysfunctionassociatedsteatoticliverdiseasefrommechanismstotherapeutics |